Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13822281 | 1.00 | USP30 (0.47) | USP30GPR119POLBJAK1JAK2 | |
| SCHEMBL2223041 | 0.91 | USP30 (0.47) | USP30GPR119POLBJAK1JAK2 | |
| SCHEMBL2223037 | 0.91 | USP30 (0.47) | USP30GPR119POLBJAK1JAK2 | |
| SCHEMBL21783090 | 0.79 | USP30 (0.58) | USP30GPR119JAK1JAK2VNN1 | |
| SCHEMBL22087745 | 0.79 | USP30 (0.58) | USP30GPR119JAK1JAK2VNN1 | |
| SCHEMBL12516842 | 0.77 | DRD2 (0.60) | POLB | |
| SCHEMBL19831677 | 0.77 | DRD2 (0.60) | POLB | |
| SCHEMBL12516846 | 0.77 | DRD2 (0.60) | POLB | |
| Hydrochloric Acid SCHEMBL14632762 | 0.77 | DRD2 (0.59) | — | |
| SCHEMBL8406581 | 0.76 | GPR119 (0.52) | USP30GPR119POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| EP-2523665-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2012-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | USP30 3492/4885GPR119 2379/4885POLB 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.